Role and Mechanism of Growth Differentiation Factor 15 in Chronic Kidney Disease

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2024 May 14

PMID 38741613

Authors

Yifang Tang

Tao Liu

Shibo Sun

Youbo Peng

Xiaoxiao Huang

Shuangquan Wang

Zhu Zhou

Affiliations

Soon will be listed here.

Abstract

GDF-15 is an essential member of the transforming growth factor-beta superfamily. Its functions mainly involve in tissue injury, inflammation, fibrosis, regulation of appetite and weight, development of tumor, and cardiovascular disease. GDF-15 is involved in various signaling pathways, such as MAPK pathway, PI3K/AKT pathway, STAT3 pathway, RET pathway, and SMAD pathway. In addition, several factors such as p53, ROS, and TNF-α participate the regulation of GDF-15. However, the specific mechanism of these factors regulating GDF-15 is still unclear and more research is needed to explore them. GDF-15 mainly improves the function of kidneys in CKD and plays an important role in the prediction of CKD progression and cardiovascular complications. In addition, the role of GDF-15 in the kidney may be related to the SMAD and MAPK pathways. However, the specific mechanism of these pathways remains unclear. Accordingly, more research on the specific mechanism of GDF-15 affecting kidney disease is needed in the future. In conclusion, GDF-15 may be a therapeutic target for kidney disease.

Citing Articles

Circulating level of growth-differentiation factor 15 and the functional outcome after acute ischemic stroke: a systematic review and meta-analysis.

Wu Y, Wei Y, He J, Zhou F Head Face Med. 2024; 20(1):72.

PMID: 39732689 PMC: 11681748. DOI: 10.1186/s13005-024-00476-4.

Association between DNA methylation predicted growth differentiation factor 15 and mortality: results from NHANES 1999-2002.

Luo H, Shen Y Aging Clin Exp Res. 2024; 36(1):234.

PMID: 39625596 PMC: 11614981. DOI: 10.1007/s40520-024-02896-3.

Growth Differentiation Factor 15 and Matrix Metalloproteinase 3 in Plasma as Biomarkers for Neuropathy and Nephropathy in Type 1 Diabetes.

Billeson K, Baldimtsi E, Wahlberg J, Whiss P Int J Mol Sci. 2024; 25(13).

PMID: 39000435 PMC: 11242093. DOI: 10.3390/ijms25137328.

References

Lee S, Rauch J, Kolch W . Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. Int J Mol Sci. 2020; 21(3). PMC: 7037308. DOI: 10.3390/ijms21031102. View

Mima A, Yasuzawa T, King G, Ueshima S . Obesity-associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio. 2018; 8(4):664-670. PMC: 5881532. DOI: 10.1002/2211-5463.12400. View

Molfino A, Amabile M, Imbimbo G, Rizzo V, Pediconi F, Catalano C . Association between Growth Differentiation Factor-15 (GDF-15) Serum Levels, Anorexia and Low Muscle Mass among Cancer Patients. Cancers (Basel). 2021; 13(1). PMC: 7795323. DOI: 10.3390/cancers13010099. View

Benes J, Kotrc M, Wohlfahrt P, Conrad M, Franekova J, Jabor A . The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease. Can J Cardiol. 2019; 35(4):462-470. DOI: 10.1016/j.cjca.2018.12.027. View

Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N . Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol. 2003; 14(8 Suppl 3):S227-32. DOI: 10.1097/01.asn.0000077407.90309.65. View

Carlsson A, Nowak C, Lind L, Ostgren C, Nystrom F, Sundstrom J . Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2019; 125(1):37-43. PMC: 7054929. DOI: 10.1080/03009734.2019.1696430. View

Hamon S, Griffin T, Islam M, Wall D, Griffin M, OShea P . Defining reference intervals for a serum growth differentiation factor-15 (GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD). Clin Chem Lab Med. 2018; 57(4):510-520. DOI: 10.1515/cclm-2018-0534. View

Wischhusen J, Melero I, Fridman W . Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020; 11:951. PMC: 7248355. DOI: 10.3389/fimmu.2020.00951. View

Blanchette-Farra N, Kita D, Konstorum A, Tesfay L, Lemler D, Hegde P . Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer. Oncogene. 2018; 37(29):4013-4032. PMC: 6054540. DOI: 10.1038/s41388-018-0243-y. View

10.

Cannata-Andia J, Martin-Carro B, Martin-Virgala J, Rodriguez-Carrio J, Bande-Fernandez J, Alonso-Montes C . Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. Calcif Tissue Int. 2020; 108(4):410-422. DOI: 10.1007/s00223-020-00777-1. View

11.

Mima A . Mitochondria-targeted drugs for diabetic kidney disease. Heliyon. 2022; 8(2):e08878. PMC: 8899696. DOI: 10.1016/j.heliyon.2022.e08878. View

12.

Zhang B, Zhang J, Sun L . In-depth profiling and analysis of host and viral microRNAs in Japanese flounder (Paralichthys olivaceus) infected with megalocytivirus reveal involvement of microRNAs in host-virus interaction in teleost fish. BMC Genomics. 2014; 15:878. PMC: 4200114. DOI: 10.1186/1471-2164-15-878. View

13.

van de Wouw J, Broekhuizen M, Sorop O, Joles J, Verhaar M, Duncker D . Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets. Front Physiol. 2019; 10:1108. PMC: 6737277. DOI: 10.3389/fphys.2019.01108. View

14.

Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, de Boer I . GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. Am J Kidney Dis. 2018; 72(4):519-528. PMC: 6153047. DOI: 10.1053/j.ajkd.2018.03.025. View

15.

Hanna R, Streja E, Kalantar-Zadeh K . Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv Ther. 2020; 38(1):52-75. PMC: 7854472. DOI: 10.1007/s12325-020-01524-6. View

16.

Bou Antoun N, Chioni A . Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. Int J Mol Sci. 2023; 24(15). PMC: 10418675. DOI: 10.3390/ijms241512222. View

17.

Dong G, Zheng Q, Ma M, Wu S, Zhang R, Yao R . Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15. Cancer Med. 2018; 7(3):820-830. PMC: 5852341. DOI: 10.1002/cam4.1330. View

18.

Nakamura H, Takada K . Reactive oxygen species in cancer: Current findings and future directions. Cancer Sci. 2021; 112(10):3945-3952. PMC: 8486193. DOI: 10.1111/cas.15068. View

19.

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

20.

Moschovaki-Filippidou F, Steiger S, Lorenz G, Schmaderer C, Ribeiro A, von Rauchhaupt E . Growth Differentiation Factor 15 Ameliorates Anti-Glomerular Basement Membrane Glomerulonephritis in Mice. Int J Mol Sci. 2020; 21(19). PMC: 7583818. DOI: 10.3390/ijms21196978. View